User contributions for Alen Antony

04:2704:27, 26 April 2024 diff hist +1,079‎ Daprodustat ‎No edit summary current

21:2121:21, 25 April 2024 diff hist +952‎ Daprodustat ‎No edit summary
20:5320:53, 25 April 2024 diff hist +1,266‎ Daprodustat ‎No edit summary
19:0719:07, 25 April 2024 diff hist +2,809‎ Daprodustat ‎No edit summary
17:2317:23, 25 April 2024 diff hist +563‎ Daprodustat ‎No edit summary
16:4716:47, 25 April 2024 diff hist +147‎ Daprodustat ‎No edit summary
15:2315:23, 25 April 2024 diff hist +1,157‎ N Daprodustat ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=daprodustat |aOrAn=a |drugClass=reversible inhibitor of HIF-PH1, PH2 and PH3. |indicationType=treatment |indication=anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. |hasBlackBoxWarning=Yes |adverseReactions=Hypertension, Abdominal pain, Dizzines, Hypersensitivity, and thrombotic vascular events like Myocardial infarction, stroke, pulmonary embolism,..."
01:5001:50, 25 April 2024 diff hist +1,145‎ Bexagliflozin ‎No edit summary current
00:5700:57, 25 April 2024 diff hist +669‎ Bexagliflozin ‎No edit summary
00:5000:50, 25 April 2024 diff hist +1,349‎ Bexagliflozin ‎No edit summary
00:1700:17, 25 April 2024 diff hist +786‎ Bexagliflozin ‎No edit summary

23:3523:35, 24 April 2024 diff hist +245‎ Bexagliflozin ‎No edit summary
23:1123:11, 24 April 2024 diff hist +1,453‎ Bexagliflozin ‎No edit summary
22:5522:55, 24 April 2024 diff hist +164‎ Bexagliflozin ‎No edit summary
21:0621:06, 24 April 2024 diff hist +76‎ N Bexagliflozin ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=bexagliflozin }}"

04:5204:52, 29 February 2024 diff hist +1,033‎ Lecanemab-irmb ‎No edit summary current
04:3004:30, 29 February 2024 diff hist +4‎ Lecanemab-irmb ‎No edit summary
02:1602:16, 29 February 2024 diff hist +607‎ N Lecanemab-irmb ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=lecanemab-irmb |aOrAn=a |drugClass=recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody |indicationType=treatment |indication=Alzheimer’s disease. This drug is ideally initiated during the early phase of dementia or mild cognitive impairment (which was the population tested in the clinical trials of this drug). |hasBlackBoxWarning=Yes |adverseReactions=Amyloid Related Imaging Abnorma..."

06:2106:21, 21 February 2024 diff hist +2,917‎ N Olutasidenib ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Olutasidenib |aOrAn=a |drugClass=isocitrate dehydrogenase-1 (IDH1) inhibitor |indicationType=treatment |indication=relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. |hasBlackBoxWarning=Yes |adverseReactions=nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, mucositis, arthralgia, fatigue, pyrexia..." current
00:2100:21, 21 February 2024 diff hist +4‎ Lenacapavir ‎No edit summary current
00:0400:04, 21 February 2024 diff hist +4,906‎ Lenacapavir ‎No edit summary

16:2916:29, 15 February 2024 diff hist +549‎ Lenacapavir ‎No edit summary
06:3006:30, 15 February 2024 diff hist +74‎ N Lenacapavir ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=lenacapavir }}"
06:0906:09, 15 February 2024 diff hist +1,439‎ Tirzepatide ‎No edit summary current
02:3202:32, 15 February 2024 diff hist +1,564‎ Tirzepatide ‎No edit summary
00:3600:36, 15 February 2024 diff hist +8,168‎ Tirzepatide ‎No edit summary

21:2521:25, 14 February 2024 diff hist +571‎ N Tirzepatide ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=tirzepatide |aOrAn=a |drugClass=glucagon-like peptide-1 (GLP-1) receptor agonist |indicationType=treatment |indication=type 2 diabetes mellitus in adults in adjunct to diet and exercise. |hasBlackBoxWarning=Yes |adverseReactions=pancreatitis,hypoglycemia with concomitant use of insulin or insulin secretagogues, acute kidney injury, severe gastrointestinal disease, acute gallbladder disease, dia..."
20:0420:04, 14 February 2024 diff hist +1,993‎ Spesolimab-sbzo ‎No edit summary current
19:1819:18, 14 February 2024 diff hist +2,223‎ Spesolimab-sbzo ‎No edit summary
07:1207:12, 14 February 2024 diff hist +17‎ Spesolimab-sbzo ‎No edit summary
07:0507:05, 14 February 2024 diff hist +3,687‎ N Spesolimab-sbzo ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Spesolimab-sbzo |drugClass=humanized monoclonal Immunoglobulin G1 antibody |indicationType=treatment |indication=generalized pustular psoriasis (GPP) flares in adults. |adverseReactions=infections, nausea, vomiting, headache, fatigue, Infusion site hematoma and bruising. |fdaLIADAdult=SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults. SPEVIGO is administer..."

22:3022:30, 12 February 2024 diff hist +2,053‎ N Mosunetuzumab-axgb ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=mosunetuzumab-axgb |aOrAn=a |drugClass=humanized monoclonal antibody |indicationType=treatment |indication=relapsing or refractory follicular lymphoma in adults after 2 or more lines of systemic therapy. |hasBlackBoxWarning=Yes |adverseReactions=cytokine release syndrome, fatigue, rash, pyrexia, and headache. |blackBoxWarningTitle=Cytokine Release Syndrome (CRS) |blackBoxWarningBody=Cytok..."

06:1306:13, 11 February 2024 diff hist +84‎ N Template:AAP ‎ Created page with "Alen Antony Pathil, M.D.[mailto:alenantony657@gmail.com]" current

Navigation menu